A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
Cell Death and Differentiation2016Vol. 23(8), pp. 1380–1393
Citations Over TimeTop 1% of 2016 papers
Antonella Tosco, Fabiola De Gregorio, Speranza Esposito, Daniela De Stefano, Ilenia Sana, Eleonora Ferrari, Angela Sepe, Laura Salvadori, Paolo Buonpensiero, A. Di Pasqua, Rosa Grassia, Carlo Antonio Leone, Stefano Guido, Giuseppe De Rosa, Sara Lusa, Gianni Bona, Gautier Stoll, Maria Chiara Maiuri, Anil Mehta, Guido Kroemer, Luigi Maiuri, Valeria Raia
Related Papers
- → WS6.3 Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation(2012)4 cited
- → 199 Effect of ivacaftor (Kalydeco™) on the pancreatic function of a child with cystic fibrosis (CF)(2016)1 cited
- → WS17.06 Impact of elexacaftor/tezacaftor/ivacaftor on lung-recruited neutrophils in cystic fibrosis(2022)
- → P040 Sweat chloride values in cystic fibrosis patients after one year on elexacaftor/tezacaftor/ivacaftor(2023)
- → P053 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis with responsive CFTR variants without previous modulators therapy(2024)